Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

Mouse Lifespan Increased 20% by Single Gene Alteration

By BiotechDaily International staff writers
Posted on 19 Sep 2013
Image: By lowering the expression of a single gene, called mTOR, scientists have extended the average lifespan of a group of mice by about 20% (Photo courtesy of the US National Institutes of Health’s (NIH) National Heart, Lung, and Blood Institute (NHLBI)).
Image: By lowering the expression of a single gene, called mTOR, scientists have extended the average lifespan of a group of mice by about 20% (Photo courtesy of the US National Institutes of Health’s (NIH) National Heart, Lung, and Blood Institute (NHLBI)).
By lowering the expression of a single gene, US researchers have extended the average lifespan of a group of lab mice by about 20%—the equivalent of raising the average human lifespan by 16 years, from 79 to 95.

The researchers targeted a gene called mTOR, which is involved in metabolism and energy balance, and may be connected with the increased lifespan associated with caloric restriction.

A detailed study of these mice, published in the August 29, 2013, of the journal Cell Reports, revealed that gene-influenced lifespan extension did not affect every organ and tissue in the same manner. For example, the mice retained better memory and balance as they aged, but their bones deteriorated more rapidly than normal.

“While the high extension in lifespan is noteworthy, this study reinforces an important facet of aging; it is not uniform,” said lead researcher Toren Finkel, MD, PhD, at the US National Institutes of Health’s (NIH) National Heart, Lung, and Blood Institute (NHLBI; Bethesda, MD, USA). “Rather, similar to circadian rhythms, an animal might have several organ-specific aging clocks that generally work together to govern the aging of the whole organism.”

Dr. Finkel, who heads the NHLBI’s Laboratory of Molecular Biology in the Division of Intramural Research, noted that these findings may help guide therapies for aging-related diseases that target specific organs, such as Alzheimer’s disease. However, additional research in these mice as well as human cells are required to figure out precisely how aging in these diverse tissues is linked at the molecular level.

The researchers modified mice that make approximately 25% of the normal amount of the mTOR protein, or about the minimum needed for survival. The engineered mTOR mice were a little smaller than average, but they otherwise appeared normal. The median lifespan for the mTOR mice was 28.0 months for males and 31.5 months for females, compared to 22.9 months and 26.5 months for normal males and females, respectively. The mTOR mice also had a longer maximal lifespan; seven of the eight longest-lived mice in this study were mTOR mice. This lifespan increase is one of the largest observed in mice up to now.

Whereas the genetically modified mTOR mice aged better overall, they revealed only selective improvement in specific organs. They typically outperformed normal mice of same age in maze and balance tests, indicating better retention of memory and coordination. Older mTOR mice also retained more muscle strength and posture. However, mTOR mice had more loss of bone volume as they aged, and they were more prone to infections at old age, suggesting a reduction of immune function.

Related Links:
US National Heart, Lung, and Blood Institute


comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.